Biochemical and Biophysical Research Communications
Interaction between S100P and the anti-allergy drug cromolyn
Introduction
The S100 proteins are calcium-binding EF-hand proteins. The calcium-induced conformational change in S100 proteins results in exposure of the hydrophobic surface between a loop region (between helix-2 and helix-3) and either helix-4 or the subsequent C-terminus to bind protein targets and regulate biological functions [1], [2]. These S100 proteins are known to be expressed in a tissue-specific and cell-specific pattern. Importantly, S100 proteins influence different functions both extracellularly and intracellularly by direct interaction with specific target proteins. Misregulation of these interactions is observed in a wide range of pathologies, thus making S100 proteins potential drug targets [3], [4]. For instance, the S100P protein is over-expressed in pancreatic, breast, lung and colon cancer cells and regulates biological function upon binding to RAGE extracellularly [5]. Thus, it is used as a clinical marker of various cancers. The direct interaction between S100P and RAGE has been confirmed by co-immunoprecipitation and activation of downstream signaling pathways, such as the extracellular regulated kinases (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) pathways [6], [7]. Therefore, elevated levels of S100P can activate the downstream pathways, including the mitogen-activated protein (MAP) kinase, ERK and NF-κB pathways, and are associated with the tumor growth in various types of cancer [7], [8], [9], [10].
Cromolyn is used to treat various diseases, including allergic rhinitis, allergic conjunctivitis, and mastocytosis [11], [12], [13]. Previous studies using affinity chromatography reported that S100P binds to cromolyn and blocks the interaction between S100P and RAGE, leading to inhibition of S100P-stimulated cell growth, invasion, and NF-κB activity in S100P-expressing BxPC-3 and MPanc-96 pancreatic cancer cells, but not in Panc-1 cells without endogenous S100P [14]. Recently, cromolyn analogs were reported to block the interaction between S100P and RAGE [15]. In the current study, we aimed to map the binding interface of S100P for cromolyn and characterized the model structure of S100P–cromolyn. Overall, the results provide significant insights into S100P–RAGE interactions.
Section snippets
Reagents and chemicals
15NH4Cl and D2O were obtained from Cambridge Isotope Laboratories. Luria Broth was obtained from AMRESCO. Cromolyn was purchased from Sigma–Aldrich. All used chemicals were analytical grade.
Expression and purification of S100P
Recombinant wild-type S100P (95 amino acids) was cloned into the pET-20b (+) T7 expression vector, over-expressed in the Escherichia coli BL21 (DE3) strain and purified using a previously reported procedure [16]. The S100P protein was eluted as a dimer from a Superdex-75 column (1.6 × 60 cm; Pharmacia). The
Fluorescence spectroscopy studies of S100P–cromolyn interactions
The cromolyn molecule showed two distinct UV absorption bands at ∼265 nm and ∼326 nm (Fig. S-1). The 326 nm absorption band of cromolyn was selected for this study. Upon excitation at 326 nm, changes in the emission of cromolyn were observed in the range from 400 to 600 nm. As shown in Fig. 1A, the addition of S100P to a 34 μM solution of cromolyn in 20 mM Tris buffer, pH = 7.5, 100 mM KCl, and 4 mM CaCl2 resulted in both a gradual shift in the emission maxima and a blue shift in the lower energy
Acknowledgments
We sincerely thank the 700 MHz Nuclear Magnetic Resonance Facility in the Department of Chemistry, National Tsing Hua University, Taiwan. We acknowledge financial support from the Ministry of Science and Technology, Taiwan (Grant number: MOST 103-2113-M-007-017-MY3 to Chin Yu) and China Medical University, Taiwan (Grant number: CMU101-N2-04 to Ruey-Hwang Chou).
References (29)
- et al.
The S100 family of EF-hand calcium-binding proteins: functions and pathology
Trends Biochem. Sci.
(1996) - et al.
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE)
J. Biol. Chem.
(2004) - et al.
S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells
Biochem. Biophys. Res. Commun.
(2004) - et al.
Evidence questioning cromolyn’s effectiveness and selectivity as a ‘mast cell stabilizer’ in mice
Lab. Invest.
(2012) - et al.
The crystal structure at 2 angstrom resolution of the Ca2+-binding protein S100P
J. Mol. Biol.
(2003) - et al.
Gromacs – a message-passing parallel molecular-dynamics implementation
Comput. Phys. Commun.
(1995) - et al.
VMD: visual molecular dynamics
J. Mol. Graph. Model.
(1996) - et al.
Molecular mechanisms of S100-target protein interactions
Microsc. Res. Tech.
(2003) - et al.
Calcium-dependent and -independent interactions of the S100 protein family
Biochem. J.
(2006) - et al.
Functions of S100 proteins
Curr. Mol. Med.
(2013)
S100P: a novel therapeutic target for cancer
Amino Acids
The RAGE ligand, S100P, has increased expression in colon cancer
J. Am. Coll. Surg.
Pathologies involving the S100 proteins and RAGE
Subcell. Biochem.
RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways
Dis. Colon Rectum
Cited by (8)
Discovery of novel small molecule inhibitors of S100P with in vitro anti-metastatic effects on pancreatic cancer cells
2020, European Journal of Medicinal ChemistryCitation Excerpt :In MOE Site-Finder, where identified cavities are ranked according to their propensity for ligand binding (PLB) score [28], the pockets identified at the dimeric interface were ranked in the top three with respect to propensity for ligand binding. In contrast to other published work on S100P-cromolyn interaction using the monomeric crystal structure, where it was reported that identified pockets on the protein were symmetrical [29], this was not observed in our study. Indeed, none of the pockets identified on the structures in the NMR ensemble show symmetricity.
S100 proteins: Diagnostic and prognostic biomarkers in laboratory medicine
2019, Biochimica et Biophysica Acta - Molecular Cell ResearchCitation Excerpt :The antiallergic drug cromolyn binds to S100P preventing RAGE activation inhibiting pancreatic tumor growth and metastasis in two animal models. Cytotoxic treatment using cromolyn in combination with gemcitabine or applying a small RAGE antagonistic peptide appears to be a promising aim for further investigations to diagnose and treat pancreatic and possibly other types of cancer [163–166], malignant melanoma [169], breast cancer [170] and nasopharyngeal carcinoma [171]. S100-fused-type proteins (e.g. hornerin, filaggrin, trichohyalin, repetin) encode multidomain proteins with an S100-like domain comprised of two different Ca2+-binding loops fused to a larger repetitive peptide via a spacer sequence.
Bis(benzofuran–thiazolidinone)s and bis(benzofuran–thiazinanone)s as inhibiting agents for chikungunya virus
2017, Antiviral ResearchCitation Excerpt :Several other synthetic compounds with a dimeric structure similar to suramin also show significant biological activities. Prominent examples include atracurium besilate (Hughes, 1986), cisatracurium besilate (Bryson and Faulds, 1997), cromoglicic acid (Penumutchu et al., 2014), daclatasvir (Press release, 2015), ombitasvir (Press release, 2014), and pentamidine (Nguewa et al., 2005). Among them, daclatasvir (trade name Daklinza) and ombitasvir (trade names Viekira Pak and Technivie) are antiviral drugs for the treatment of hepatitis C virus infection.
The role of S100 proteins and their receptor RAGE in pancreatic cancer
2015, Biochimica et Biophysica Acta - Molecular Basis of DiseaseCitation Excerpt :Extracellular S100P was shown to bind to RAGE [33] and to stimulate cell-growth survival and invasion (Fig. 2A) [30]. As a result, several RAGE/S100P inhibitors were developed and used to block RAGE-dependent, pancreatic-cancer cell or tumor growth [7,30,34–37]. A S100P-derived peptide, which blocks the RAGE/S100P interaction, inhibited pancreatic-tumor growth and metastasis formation in a pancreatic ductal adenocarcinoma mouse model [30,34].
S100s and HMGB1 Crosstalk in Pancreatic Cancer Tumors
2023, BiomoleculesFriend or foe: S100 proteins in cancer
2020, Cancers